Genomic based tratment approach of symptomatic naive Waldenström Macroglobulinemia #lymsm

For a fantastic overview of the global burden of hematologic cancers check out this article in Blood Cancer Journal — it is full of detailed tables and figures to save and bookmark. #ASCO23 #MedTwitter #OpenAccess nature.com/articles/s4140…

In this issue of Haematologica, Chen et al.describe mechanisms by which monoclonal gammopathy (MG) can cause tissue damage and review the literature and the case for MG screening. haematologica.org/article/view/h…

CONGRESS #EHA2023 | Sirpa Leppa University of Helsinki presents initial safety data from ph III POLAR BEAR trial. R-pola-mini-CHP & R-mini-CHOP had comparable safety profile & were tolerable in elderly or frail pts with DLBCL. GI events were more common in pola group. #lymhoma #lym #lymsm

T-cell-engaging bispecific antibodies in cancer ⁦The Lancet⁩ thelancet.com/journals/lance…

CONGRESS #17ICML| Late-breaking abstract Franck Morschhauser at Centre Hospitalier Universitaire de Lille presented phase 2 TRANSCEND FL study of liso-cel in pts with R/R FL. ORR=97%, CR=94% with low rates of Gr ≥3 TEAEs of CRS/NEs, prolonged cytopenia, & infection #lymsm #leusm

DTI should be reported in all patients newly diagnosed with MCL enrolling in clinical trials; steps must be taken to avoid selection bias. loom.ly/6wvKMBg #clinicaltrialsandobservations

Chu et al. Global epidem of NHL. • 2020: 545k cases & 260k deaths • highest incidence Aus / NZ • highest mort rate Zimbabwe • ⬆️ assoc with obesity • mort rates ⬇️ most countries • projected 43% ⬆️ over 2y Clinics will be getting busier 😬 #lymsm frontiersin.org/articles/10.33…

#lymsm Ever wondered about the impact of M protein in your patients with MZL? Read our new paper spearheaded by Narendranath Epperla The James and Adam Olszewski MD, out now in Blood Advances ASH ashpublications.org/bloodadvances/…

A new guideline from ASTCT provides clinical practice recommendations for transplant and cellular therapies in diffuse large b-cell lymphoma. Review the #openaccess guideline: ow.ly/4VtQ50P9TuY Elsevier Hematology #LBCL Mehdi Hamadani, MD Narendranath Epperla

Beyond youth: Understanding CAR T cell fitness in the context of immunological aging - NEW by Julia Han Noll 🧵sciencedirect.com/science/articl…

Genetic-subtype guided R-CHOP-X treatment resulted in superior DLBCL outcomes vs R-CHOP in the randomized phase 2 GUIDANCE-01 trial. Great effort exploiting subtype-specific vulnerabilities of DLBCL. Phase 3 trial vs R-CHOP is already ongoing. Cancer Cell cell.com/cancer-cell/fu…

🚨Largest study to date RWE SOC CART in SCNSL led by Narendranath Epperla ORR 68% with CR 57% and median PFS 3.3 months. Unfortunately high high CR rates but responses not durable doi.org/10.1186/s13045… Nirav Shah Loretta J. Nastoupil, MD Jane N. Winter Pallawi Torka Hamza Hashmi

#ASH23 Late breaking abstract 2 The long-awaited SYMPATICO trial Ibr+Ven vs Ibr+pbo RCT in R/R MCL - med PFS 31.9 vs 22.1 months, HR 0.65 p = 0.005 - median OS 44.9 vs 38.6 mo (not significant) ash.confex.com/ash/2023/webpr… h/t David Russler-Germain, MD/PhD #lymsm

Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study | Blood Advances | American Society of Hematology ashpublications.org/bloodadvances/…

#ScienceSaturday Can dietary nutrients help the immune system kill #cancer cells? In this study, researchers screened 255 circulating nutrients for the ability to enhance T cell activity and found that the long-chain fatty acid TVA (Trans-vaccenic acid) could enhance the

We are looking forward to working on this more- adding ⬆️ cases & analyses (45-49% vs <45% split was arbitrary but may be relevant). Much more work in this area is needed as these #lymphoma pts are often excluded from clinical trials. Narendranath Epperla Raul Cordoba, MD, PhD #ASH23 #CardioOnc

Multicenter CNS involvement in HGBL NOS Narendranath Epperla: - 160 pts, 7% baseline CNSi - CNSi➡️MYC-R, testicular/female pelvic - no diff in PFS/OS for CNSi vs not (2-yr PFS 53-55%) - 11% CNS relapse at 3 years - mOS 6-7 mos at relapse regardless of CNSi #lymsm ashpublications.org/bloodadvances/…

nejm.org/doi/full/10.10…

Exciting discovery: CSF flow isn't confined to the brain and spinal cord—it also extends to peripheral nerves! Science Magazine science.org/doi/10.1126/sc… Groundbreaking research from UF Health FLORIDA #neurotwitter #neuroscience #AcademicChatter